在浅表和全身性念珠菌病、脑膜隐球菌病及肺曲霉病的啮齿动物模型中对Bay R 3783进行评估。
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.
作者信息
Hector R F, Yee E
机构信息
Cutter Biological, Berkeley, California 94710.
出版信息
Antimicrob Agents Chemother. 1990 Mar;34(3):448-54. doi: 10.1128/AAC.34.3.448.
Abstract
The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis. Overall, Bay R 3783 was comparable or slightly superior to fluconazole and markedly superior to itraconazole and ketoconazole in both survival and short-term organ load experiments in models of candidiasis and cryptococcosis but was less effective than amphotericin B. Of the antifungal agents tested, only Bay R 3783 and itraconazole showed any efficacy in the model of pulmonary aspergillosis.
摘要
在浅表和全身性念珠菌病、脑膜脑隐球菌病以及肺曲霉病的啮齿动物模型中，将三唑类药物Bay R 3783与氟康唑、伊曲康唑、酮康唑和两性霉素B进行了比较。总体而言，在念珠菌病和隐球菌病模型的生存和短期器官负荷实验中，Bay R 3783与氟康唑相当或略优于氟康唑，明显优于伊曲康唑和酮康唑，但比两性霉素B效果差。在所测试的抗真菌药物中，只有Bay R 3783和伊曲康唑在肺曲霉病模型中显示出任何疗效。
相似文献
1
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.在浅表和全身性念珠菌病、脑膜隐球菌病及肺曲霉病的啮齿动物模型中对Bay R 3783进行评估。
Antimicrob Agents Chemother. 1990 Mar;34(3):448-54. doi: 10.1128/AAC.34.3.448.
2
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.新型口服三唑类抗真菌药ER-30346在曲霉病、念珠菌病和隐球菌病实验模型中的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
3
Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.氟康唑（UK-49,858）对小鼠实验性曲霉病和隐球菌病的疗效。
J Antimicrob Chemother. 1987 May;19(5):663-70. doi: 10.1093/jac/19.5.663.
4
Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.小鼠实验性念珠菌病、隐球菌病、曲霉病和万氏皮炎的联合治疗
Chemotherapy. 1987;33(5):381-95. doi: 10.1159/000238524.
5
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.新型口服三唑类抗真菌药ER-30346的体外和体内抗真菌活性，其具有广谱抗真菌谱。
Antimicrob Agents Chemother. 1996 Oct;40(10):2237-42. doi: 10.1128/AAC.40.10.2237.
6
In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.伊曲康唑的体外抗真菌谱以及新旧抗真菌药物治疗系统性真菌病的情况。
Chemotherapy. 1992;38 Suppl 1:3-11. doi: 10.1159/000239046.
7
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.伊曲康唑与氟康唑治疗兔隐球菌性脑膜炎和念珠菌性肾盂肾炎的比较。
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
8
Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis.三唑类药物Bay R 3783在球孢子菌病、芽生菌病和组织胞浆菌病小鼠模型中的治疗效果。
Antimicrob Agents Chemother. 1990 Jun;34(6):1132-8. doi: 10.1128/AAC.34.6.1132.
9
Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis.唑类药物在体外及肺部曲霉病实验模型中对曲霉的比较。
Chemotherapy. 1992;38(2):118-26. doi: 10.1159/000238951.
10
[Therapy of pulmonary mycoses].[肺部真菌病的治疗]
Dtsch Med Wochenschr. 1992 Nov 6;117(45):1725-9. doi: 10.1055/s-2007-1024318.
引用本文的文献
1
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion.新型隐球菌的脲酶表达促进微血管隔离，从而增强对中枢神经系统的侵袭。
Am J Pathol. 2004 May;164(5):1761-71. doi: 10.1016/S0002-9440(10)63734-0.
2
T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.T-8581，一种新型口服和胃肠外给药均有效的三唑类抗真菌药物：体内外评价
Antimicrob Agents Chemother. 1997 Jan;41(1):30-4. doi: 10.1128/AAC.41.1.30.
3
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.新型口服三唑类抗真菌药ER-30346在曲霉病、念珠菌病和隐球菌病实验模型中的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
4
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.新型口服三唑类抗真菌药ER-30346的体外和体内抗真菌活性，其具有广谱抗真菌谱。
Antimicrob Agents Chemother. 1996 Oct;40(10):2237-42. doi: 10.1128/AAC.40.10.2237.
5
Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.伊曲康唑治疗实验性肺曲霉病：与两性霉素B的比较、与环孢素A的相互作用以及治疗反应与血浆中伊曲康唑浓度的相关性
Antimicrob Agents Chemother. 1994 Jun;38(6):1303-8. doi: 10.1128/AAC.38.6.1303.
6
Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.免疫抑制或中性粒细胞减少患者侵袭性肺曲霉病的预防策略。
Antimicrob Agents Chemother. 1994 May;38(5):911-7. doi: 10.1128/AAC.38.5.911.
7
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.SCH51048在肺曲霉病实验模型中的评估。
Antimicrob Agents Chemother. 1995 Jun;39(6):1345-8. doi: 10.1128/AAC.39.6.1345.
8
Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.DBA/2N小鼠在系统性念珠菌病以及肺部和系统性曲霉病模型中的应用。
Infect Immun. 1990 May;58(5):1476-8. doi: 10.1128/iai.58.5.1476-1478.1990.
9
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.1,3-β-D-葡聚糖合成抑制剂L-671,329、L-646,991、四氢棘白菌素B和丘疹青霉素L-687,781的体外抗真菌活性及体内疗效
Antimicrob Agents Chemother. 1992 Aug;36(8):1648-57. doi: 10.1128/AAC.36.8.1648.
10
Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.尼可霉素与唑类药物在体外和体内对白色念珠菌的协同作用。
Antimicrob Agents Chemother. 1992 Jun;36(6):1284-9. doi: 10.1128/AAC.36.6.1284.
本文引用的文献
1
Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals.含咪唑抗真菌药物对白色念珠菌中甾醇生物合成的抑制作用。
J Gen Microbiol. 1980 Mar;117(1):253-5. doi: 10.1099/00221287-117-1-253.
2
Mammary gland contamination as a means of establishing long-term gastrointestinal colonization of infant mice with Candida albicans.通过乳腺污染将白色念珠菌定殖于新生小鼠胃肠道以建立长期定殖的方法。
Infect Immun. 1982 Nov;38(2):788-90. doi: 10.1128/iai.38.2.788-790.1982.
3
Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole.联苯苄唑和克霉唑。它们的作用方式以及联苯苄唑具有杀菌作用的可能原因。
Arzneimittelforschung. 1984;34(2):139-46.
4
R 51211 (itraconazole) therapy of murine cryptococcosis.R 51211（伊曲康唑）对小鼠隐球菌病的治疗
Sabouraudia. 1984;22(6):445-53. doi: 10.1080/00362178485380721.
5
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis.伊曲康唑与酮康唑治疗实验性念珠菌性阴道炎的比较。
Antimicrob Agents Chemother. 1984 Aug;26(2):266-7. doi: 10.1128/AAC.26.2.266.
6
Cryptococcal meningitis in patients with AIDS.艾滋病患者的隐球菌性脑膜炎
J Infect Dis. 1988 Apr;157(4):624-8. doi: 10.1093/infdis/157.4.624.
7
The epidemiology of AIDS in the U.S.
Sci Am. 1988 Oct;259(4):72-81. doi: 10.1038/scientificamerican1088-72.
8
Adrenal response to corticotropin during therapy with itraconazole.伊曲康唑治疗期间肾上腺对促肾上腺皮质激素的反应。
Antimicrob Agents Chemother. 1987 Apr;31(4):647-9. doi: 10.1128/AAC.31.4.647.
9
Itraconazole treatment of experimental systemic candidiasis in male rats.
J Med Vet Mycol. 1987 Apr;25(2):125-6. doi: 10.1080/02681218780000171.
10
Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole.
Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S77-86. doi: 10.1093/clinids/9.supplement_1.s77.
Zotero 插件